VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

Stock Information for VYNE Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VYNE Therapeutics Inc.

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.